Compare Regeneron Pharmaceuticals Inc (REGN) vs Zillow Group Inc Class C (Z) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

Zillow Group (Z) trades at $33.03, down 2.58% amid legal headwinds, with technicals neutral and fundamentals showing improving profitability. Revenue grew to $2.58B in 2025 with net income turning positive at $23M, though valuation multiples remain elevated with a P/E of 132.04. The stock faces significant legal overhang from multiple class-action lawsuits alleging securities fraud related to an anticompetitive agreement.

The outlook is cautious; while earnings beat expectations in two recent quarters and analyst consensus targets $57.67, near-term risks from litigation and a high P/E ratio temper upside potential. Investment appeal hinges on legal resolution and sustained margin expansion beyond current modest levels.